Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound annual growth rate of 23.22%. Active Companies from around the markets with current developments this week include: MindWalk Holdings Corp. (NASDAQ: HYFT), AbCellera Biologics Inc. (NASDAQ: ABCL), Eli Lilly and Company (NYSE: LLY), Twist Bioscience Corporation (NASDAQ: TWST) and Tempus AI, Inc. (NASDAQ: TEM).
AUSTIN, Texas, October 01, 2026--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced the appointment of Kim Remizowski to its Board of Directors as an independent director, effective September 29, 2026. Mr. Remizowski will serve on the Audit Committee and the Compensation, Nomination and Governance Committee. The Board has determined that he qualifies as an independent director under Nasdaq listing rules and as an audit committee financial expert under a
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Advanced Micro Devices (NasdaqGS:AMD) and Advantech announced a collaboration to accelerate Edge AI workloads using AMD embedded and GPU platforms. MindWalk has moved OpenFold3 into production on AMD Instinct GPUs, supported by inference microservices for life sciences workflows. The Advantech alliance focuses on scalable, partner-led Edge AI solutions, while MindWalk highlights regulated, production-grade scientific use cases on AMD hardware. The Advantech Edge AI work and MindWalk...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.